CRSP
CRISPR Therapeutics AGHealthcare·Biotechnology
$56.18
$5.4B market cap
Revenue
$2.3M
Free Cash Flow
$-202.5M
Rev Growth
+0.0%
FCF Margin
-8719.7%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and
2-Year Price History
$50.36-6.3%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 1.5 | -125.9 | -130.3 | -122.9 | -108.9 | -109.4 | -0.5 | 2,442 | 787.6 | 96.1 | -40.2% | -- | -- |
| Act | 2025-Q4 | 0.9 | -149.1 | -154.8 | -130.6 | -92.6 | -93.1 | -0.5 | 1,976 | 394.9 | 89.9 | -60.7% | -- | -- |
Valuation & Metrics
Market Stats
Price$56.18
Market Cap$5.4B
Enterprise Value$3.8B
P/S Ratio2333.6x
P/FCF--
EV/FCF--
FCF Margin (TTM)-8719.7%
FCF Yield-3.7%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$2.3M
Net Income$-253.5M
Free Cash Flow$-202.5M
Revenue Growth (YoY)+0.0%
EBITDA Margin-11844.6%
Net Margin-10919.2%
FCF Margin-8719.7%
CapEx % of Revenue44.0%
SBC % of Revenue778.5%
ROIC-50.5%
WC Change % Rev108.1%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares22.5M
Days to Cover11.9
Change (vs Prior)-1.2%
Need at least 2 settlement dates for chart
Employees
Headcount393
Revenue / Employee$5,908
Gross Profit / Employee$-273,005
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
57.9%(+19.0% YoY)
464 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
17.5%(+11.1% YoY)
13 filers
Vanguard, iShares, SPDR
Market makers
0.8%(+0.3% YoY)
9 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| ARK Investment Management LLC | $538M | $47.55 | +$37.7M | +$54.6M | -1.6% | $12.86B |
| BlackRock, Inc.Passive | $365M | $50.27 | +$8.2M | +$241M | -0.2% | $5.69T |
| Orbis Allan Gray Ltd | $290M | $52.64 | +$7.4M | +$216M | -0.9% | $23.40B |
| Capital World Investors | $225M | $47.57 | +$205M | +$225M | — | $732.46B |
| STATE STREET CORPPassive | $189M | $53.24 | +$10.9M | +$74.7M | -0.2% | $2.89T |
| GSK plc | $153M | $52.44 | +$0 | +$153M | -26.0% | $599M |
| T. Rowe Price Investment Management, Inc. | $140M | $52.68 | −$13.0M | −$40.2M | -1.3% | $145.22B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $113M | $50.57 | +$6.1M | +$63.3M | +2.3% | $1.61T |
| SR ONE CAPITAL MANAGEMENT, LP | $97.0M | $66.53 | +$0 | +$47.1M | -6.1% | $915M |
| FMR LLC | $93.0M | $62.70 | +$35K | +$673K | -0.0% | $1.89T |
| Nikko Asset Management Americas, Inc. | $88.2M | $60.77 | −$5.0M | −$32.6M | -1.1% | $7.07B |
| Sumitomo Mitsui Trust Group, Inc. | $88.2M | $60.77 | −$5.0M | −$32.6M | +1.8% | $154.47B |
| UBS Group AG | $83.8M | $44.38 | −$36.2M | −$14.7M | -0.3% | $562.11B |
| TWO SIGMA INVESTMENTS, LP | $70.5M | $44.21 | +$48.2M | +$14.0M | -0.9% | $117.03B |
| EcoR1 Capital, LLC | $66.1M | $68.16 | +$0 | +$0 | -4.8% | $2.34B |
| Capital International Investors | $56.5M | $57.89 | −$224M | −$232M | +0.4% | $424.78B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $54.4M | $47.57 | +$54.4M | +$54.4M | — | $4.04T |
| NEA Management Company, LLC | $50.4M | $60.77 | +$0 | −$25.2M | -3.3% | $1.76B |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $49.4M | $57.44 | +$436K | +$15.5M | +0.7% | $645.81B |
| BANK OF AMERICA CORP /DE/ | $46.8M | $54.92 | −$5.4M | −$19.2M | -0.1% | $1.36T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
-2.20%
avg per quarter
Holders (ex-self)
-2.61%
excl. this stock
Buyers (this Q)
+0.01%
145 buyers · $0.46B in
Sellers (this Q)
+0.14%
131 sellers · $0.51B out
alpha coverage: 97% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+0.1%
how holders react when this stock falls
On quiet Qs
-14.0%
−10% to +10% baseline
On rallies (+10%+)
-11.2%
how they react when this stock rises
Holders' portfolio flow this Q
+4.9%
inflows — adds are organic
Sellers' portfolio flow this Q
-12.8%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-2.7%
Holder mid (any stock)
-4.3%
Holder rally (any stock)
-3.6%
Biggest decreases this quarter
Capital International Investors−$224Mα+0.4UBS Group AG−$36.2Mα-0.3T. Rowe Price Investment Management, Inc.−$13.0Mα-1.3SUSQUEHANNA INTERNATIONAL GROUP, LLP−$12.4Mα-0.6Contrarius Group Holdings Ltdexited−$8.2MNo Street GP LPexited−$6.6MBANK OF AMERICA CORP /DE/−$5.4Mα-0.1Beck Bode, LLCexited−$5.2MNikko Asset Management Americas, Inc.−$5.0Mα-1.1Sumitomo Mitsui Trust Group, Inc.−$5.0Mα+1.8
New buyers this quarter
Top-5 holders · 43.8%
ARK Investment Management LLC--
BlackRock, Inc.--
Orbis Allan Gray Ltd--
Capital World Investors--
STATE STREET CORP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
ARK Investment Management LLC11.3MCapital International Investors1.2MNikko Asset Management Americas, Inc.1.9MNEA Management Company, LLC1.1MOrbis Allan Gray Ltd6.1MSumitomo Mitsui Trust Group, Inc.1.9MT. Rowe Price Investment Management, Inc.3.0MCapital World Investors4.7MPRICE T ROWE ASSOCIATES INC /MD/105KMACQUARIE GROUP LTD—
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$66.001750.0%
Last Year (9 analysts)$66.221790.0%
Current Price$56.18
Analyst Ratings
22
14
Buy: 22Hold: 14Sell: 2Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$52.64M
2 txns · 2 insiders · 1,009,812 sh
Sells ($, 12mo)
$17.42M
20 txns · 4 insiders · 299,371 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-23 | SELL | KASINGER JAMES R. | officer: General Counsel and Secretary | 3,182 | $46.78 | $149K | $4.41M |
| 2026-03-23 | SELL | Prasad Raju | officer: Chief Financial Officer | 3,708 | $46.78 | $173K | $728K |
| 2026-03-23 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 10,020 | $46.78 | $469K | $11.95M |
| 2026-03-16 | SELL | KASINGER JAMES R. | officer: General Counsel and Secretary | 3,450 | $48.26 | $166K | $4.40M |
| 2026-03-16 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 10,349 | $48.26 | $499K | $11.86M |
| 2026-03-16 | SELL | Patel Naimish | officer: Chief Medical Officer | 3,150 | $48.26 | $152K | $634K |
| 2026-03-16 | SELL | Prasad Raju | officer: Chief Financial Officer | 9,869 | $48.26 | $476K | $665K |
| 2026-03-11 | SELL | KASINGER JAMES R. | officer: General Counsel and Secretary | 2,800 | $52.80 | $148K | $4.64M |
| 2026-03-11 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 9,798 | $52.80 | $517K | $12.44M |
| 2026-02-19 | SELL | KASINGER JAMES R. | officer: General Counsel and Secretary | 2,112 | $52.58 | $111K | $4.48M |
| 2026-02-19 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 6,967 | $52.58 | $366K | $11.89M |
| 2026-01-22 | SELL | Prasad Raju | officer: Chief Financial Officer | 34,972 | $60.19 | $2.10M | $407K |
| 2026-01-22 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 60,000 | $60.23 | $3.61M | $8.08M |
| 2026-01-20 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 30,000 | $51.75 | $1.55M | $10.05M |
| 2026-01-06 | SELL | Prasad Raju | officer: Chief Financial Officer | 29,700 | $60.16 | $1.79M | $407K |
| 2025-12-22 | SELL | Prasad Raju | officer: Chief Financial Officer | 10,000 | $55.95 | $560K | $379K |
| 2025-10-17 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 50,895 | $67.91 | $3.46M | $17.26M |
| 2025-10-14 | SELL | KASINGER JAMES R. | officer: General Counsel and Secretary | 1,076 | $66.60 | $72K | $5.55M |
| 2025-10-14 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 4,242 | $66.60 | $283K | $13.66M |
| 2025-08-18 | SELL | Kulkarni Samarth | director, officer: Chief Executive Officer | 13,081 | $58.15 | $761K | $12.04M |
Order Flow (FINRA, ~3w lag)
27.7%retail+1.4pp
21.4%dark-1.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
CRISPR Therapeutics AG: The Milestone Cliff and the 10-Million-Share Dilution Engine
Overall Risk
6/10
Fraud
2/10
Dilution
9/10
Insolvency
3/10
Earnings Overstated
4/10
Hidden Liabilities
7/10
Legal
8/10
Audit Warnings
1/10
Hidden Upside
7/10
Contextually Acceptable
8/10